

STATE OF NEW YORK

599

2023-2024 Regular Sessions

IN SENATE

January 5, 2023

Introduced by Sens. SALAZAR, MAY -- read twice and ordered printed, and when printed to be committed to the Committee on Health

AN ACT to amend the insurance law, in relation to requiring certain manufacturers of prescription drugs to notify the superintendant of any proposed increase of the wholesale acquisition cost of such prescription drugs

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

1 Section 1. The insurance law is amended by adding a new section 111-a
2 to read as follows:

3 § 111-a. Notification of prescription drug price increases by manufac-
4 turers. (a) This section shall apply to a manufacturer of a prescription
5 drug that is purchased or reimbursed in this state by any of the follow-
6 ing:

7 (1) An insurance company authorized in this state to write accident
8 and health insurance, a company organized pursuant to article forty-
9 three of this chapter, a municipal cooperative health benefit plan
10 established pursuant to article forty-seven of this chapter, an organ-
11 ization certified pursuant to article forty-four of the public health
12 law, an institution of higher education certified pursuant to section
13 one thousand one hundred twenty-four of this chapter, or the New York
14 state health insurance plan established pursuant to article eleven of
15 the civil service law; or

16 (2) A pharmacy benefit manager, including an entity that directly or
17 through an intermediary, manages the prescription drug coverage provided
18 by a health insurer under a contract or policy delivered or issued for
19 delivery in this state or a health plan subject to section three hundred
20 sixty-four-j of the social services law, including the processing and
21 payment of claims for prescription drugs, the performance of drug utili-
22 zation review, the processing of drug prior authorization requests, the
23 adjudication of appeals or grievances related to prescription drug

EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[-] is old law to be omitted.

LBD00641-01-3

1 coverage, contracting with network pharmacies, and controlling the cost
2 of covered prescription drugs.

3 (b) (1) A manufacturer of a prescription drug with a wholesale acqui-
4 sition cost of more than forty dollars for a course of therapy shall
5 notify the superintendent, his or her deputy or other officer designated
6 by the superintendent, if the increase in the wholesale acquisition cost
7 of such prescription drug is more than ten percent, including the
8 proposed increase and the cumulative increases that occurred within the
9 previous twenty-four months. For purposes of this section, a "course of
10 therapy" is defined as either of the following:

11 (i) the recommended daily dosage units of a prescription drug pursuant
12 to its prescribing label as approved by the federal Food and Drug Admin-
13 istration for thirty days; or

14 (ii) the recommended daily dosage units of a prescription drug pursu-
15 ant to its prescribing label as approved by the federal Food and Drug
16 Administration for a normal course of treatment that is less than thirty
17 days.

18 (2) (i) The notice required by paragraph (1) of this subsection shall
19 be provided in writing to the superintendent at least sixty days prior
20 to the planned effective date of the increase and shall include the
21 proposed increase and the cumulative increases that occurred within the
22 previous twenty-four months.

23 (ii) The superintendent shall forthwith publish the notice required by
24 paragraph (a) of this subdivision on the department of financial
25 services website within five days of its receipt.

26 (3) (i) The notice required by paragraph (1) of this subsection shall
27 include the date of the increase, the current wholesale acquisition cost
28 of the prescription drug, and the dollar amount of the future increase
29 in the wholesale acquisition cost of the prescription drug.

30 (ii) The notice required by paragraph (1) of this subsection shall
31 include a statement regarding whether a change or improvement in the
32 drug necessitates the price increase. If so, the manufacturer shall
33 describe the change or improvement.

34 (4) Information supplied by a manufacturer pursuant to this section
35 that the manufacturer has designated as a trade secret shall be consid-
36 ered confidential and a trade secret and shall not be disclosed directly
37 or indirectly by the superintendent. Notwithstanding the foregoing
38 sentence, the superintendent shall be permitted to disclose information
39 in an aggregated format if such aggregate information cannot directly or
40 indirectly be used to identify trade secret information related to a
41 specific manufacturer or the manufacturer's prescription drug, including
42 but not limited to any information related to pricing for the manufac-
43 turer's prescription drug that has been designated as a trade secret.

44 (5) In the event that a manufacturer of a prescription drug subject to
45 this section does not report the information required in paragraph (1)
46 of this subsection, the superintendent is authorized to impose any
47 penalty or remedy authorized by this chapter, after notice and a hear-
48 ing, against such manufacturer of up to five thousand dollars per day
49 for every day after the reporting period described in this section that
50 the required information is not reported.

51 § 2. This act shall take effect immediately.